IGBA Launches First Global Biosimilars Week

Sunday November 15, 2020

IGBA Global Biosimilars Week

Contact: [email protected]

Geneva, November 16, 2020 – Today the International Generic and Biosimilar Medicines Association (IGBA) launched the first ever Global Biosimilars Week, which is aimed at raising the awareness of biosimilar medicines worldwide through a globally aligned educational initiative.

 IGBA Global Biosimilars Week will take place from November 16 to 20, and will be supported by a dedicated globalbiosimilarsweek.org website that contains resources and information for everyone, from patients to doctors. Biosimilars benefits, regulation, clinical use and market adoption will be covered.

There is a wealth of information available globally about biosimilar medicines and the real-world evidence supporting their safety, efficacy and use,” explained Hanan Sboul, Chair of the IGBA. “Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support healthcare systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis.”

With this awareness campaign, the IGBA is providing a one-stop solution for anyone wanting to know more about biosimilar medicines. We invite all stakeholders to get involved and engage in the conversation by following along on social media using the hashtag #GlobalBiosimilarsWeek,said Erika Satterwhite, Chair of the IGBA Biosimilars Committee.  

IGBA member companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. To date there have been more than 300 biosimilar approvals in jurisdictions representative of the IGBA’s membership, covering more than 10 therapeutic areas including oncology, rheumatoid arthritis, psoriasis, inflammatory bowel disease, growth disorders, nephrology, fertility and diabetes.

Biosimilars are an important part of the health care discussion with the potential to lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines in the United States. Biosimilars are safe and effective, and in the United States experts estimate that biosimilars could be priced 10 to 35 percent less than their brand-name drug competitors, increasing access to treatment options.

Join the Biosimilars Council along with 17 other IGBA associations in building awareness. Follow the hashtag #GlobalBiosimilarsWeek to learn more about how biosimilar medicines can benefit patients globally and in the U.S. and use the social toolkit to join the conversation with daily themes throughout the week. Visit globalbiosimilarsweek.org for more information.

About IGBA

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients worldwide have access to high quality, pro-competitive medicines. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.